Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis.

Seok-Young KimSeung Yong ShinSoo Jung ParkJong Pil ImHyo Jong KimKang Moon LeeJi Won KimSung-Ae JungJun LeeSang-Bum KangSung Jae ShinEun Sun KimYou Sun KimTae Oh KimHyun-Soo KimDong Il ParkHyung Kil KimEun Soo KimYoung-Ho KimDennis TengJong-Hwa KimWonyong KimMaham SaeedJung Min MoonKisung KimChang Hwan ChoiHyung-Kyoon Choi

Published in: Therapeutic advances in gastroenterology (2023)

Fecal metabolites in UC patients markedly differ from those in HC, and the levels in RM are changed similarly to those in HC after anti-TNF therapy. Moreover, 3-hydroxybutyrate, lysine, phenethylamine, and dodecanoate are suggested as potential therapeutic targets for UC. A prediction model of long-term remission based on lipid biomarkers may help implement personalized treatment.

Keyphrases

ulcerative colitis
rheumatoid arthritis
end stage renal disease
ejection fraction
prognostic factors
stem cells
disease activity
peritoneal dialysis
risk assessment
patient reported outcomes
systemic lupus erythematosus